Skip to main content
Signal8

NEXGEL, INC. (NXGL) Form 8-K — Nov 18, 2026

$NXGLForm 8-KItems 5.02, 8.01Filed Nov 18, 2026, 5:24 PM ET0001493152-26-053107Original filing

NexGel's Board elected Aviv Argaman, a full-time professional investor and founder of Asymmetry Point Capital, as an independent director effective November 12, 2026, and appointed him to a newly formed special committee on November 18, 2026. The special committee — chaired by Steve Ciardiello with Jerome Zeldis and Argaman — will evaluate and negotiate the proposed business combination with Fountainhead LifeSciences and its affiliates, including Sequence LifeScience and NVISION Biomedical Technologies. No definitive merger agreement has been signed yet.

Key figures

Note interest rate
10%
Reverse split ratio
1-for-20 (effective October 12, 2026)
Existing warrant shares
41667
Conversion price per share
5.5
Reduced warrant exercise price
13
Original warrant exercise price
16
Asymmetry point conversion shares
363636
Asymmetry point note purchases usd
2000000

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    NEXGEL, INC. (NXGL) Form 8-K — Nov 18, 2026: AI Analysis | Signal8